Clinical Features and Prognostic Significance of TCF3-PBX1 Fusion Gene in Chinese Children with Acute Lymphoblastic Leukemia by Using a Modified ALL-BFM-95 Protocol

REFERENCES

• Hunger SP, Loh ML, Whitlock JA, et al. Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013;60:957–963.
   Google Scholar
• Stary J, Zimmermann M, Campbell M, et al. Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002. J Clin Oncol. 2013;32:174–184.
   Google Scholar
• Moorman AV, Ensor HM, Richard SM, et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol. 2010;11:429–438.
   Google Scholar
• Pui C-H, Carroll WL, Meshinchi, et al. Biology, risk stratification, and therapy of pediatric acute leukemia: an update. J Clin Oncol. 2011;29:551–565.
   Google Scholar
• Hunger SP: Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: clinical features and molecular pathogenesis. Blood 1996;87:1211–1224.
   Google Scholar
• Crist WM, Carroll AJ, Shuster JJ, et al. Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19) (q23; p13): a Pediatric Oncology Group study. Blood. 1990;76:117–122.
   Google Scholar
• Hunger SP, Galili N, Carroll AJ, et al. The t (1; 19) (q23; p13) results in consistent fusion of E2A and PBXl coding sequences in acute lymphoblastic leukemia. Blood. 1991;77:687–693.
   Google Scholar
• Uckun FM, Sensel MG, Sather HN, et al. Clinical significance of translocation t (1; 19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: A report from the Children's Cancer Group. J Clin Oncol. 1998;16:527–535.
   Google Scholar
• Felice MS, Gallego MS, Alonso CN, et al. Prognostic impact of t (1; 19) /TCF3–PBX1 in childhood acute lymphoblastic leukemia in the context of Berlin–Frankfurt–Munster-based protocols. Leuk Lympho. 2011;52:1215–1221.
   Google Scholar
• Andersen MK, Autio K, Barbany G, et al. Paediatric B-cell precursor acute lymphoblastic leukaemia with t (1;19)(q23;p13): clinical and cytogenetic characteristics of 47 cases from the Nordic countries treated according to NOPHO protocols. Br J Haematol. 2011;155:235–243.
   Google Scholar
• Jeha S, Pei D, Raimondi SC, et al. Increased risk for CNS relapse in pre-B cell leukemia with the t (1; 19) /TCF3-PBX1. Leukemia. 2009;23:1406–1409.
   Google Scholar
• Pui C-H, Campana D, Pei DQ, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360:2730–2741.
   Google Scholar
• Moricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111:4477–4489.
   Google Scholar
• Gao C, Zhao XX, Li WJ, et al. Clinical features, early treatment responses, and outcomes of pediatric acute lymphoblastic leukemia in China with or without specific fusion transcripts: A single institutional study of 1,004 patients. Am J Hematol. 2012;87:1022–1027.
   Google Scholar
• Hunger SP, Fall MZ, Camitta BM., et al. E2A-PBX1 chimeric transcript status at end of consolidation is not predictive of treatment outcome in childhood acute lymphoblastic leukemia with a t (1; 19) (q23; p13): a Pediatric Oncology Group study. Blood. 1998;91:1021–1028.
   Google Scholar
• Kager L, Lion T, Attarbaschi A, et al. Incidence and outcome of TCF3-PBX1 positive acute lymphoblastic leukemia in Austrian children. Haematologica. 2007;92:1561–1564.
   Google Scholar
• Tsuchida M, Ohara A, Manabe A, et al. Long-term results of Tokyo Children's Cancer Study Group trials for childhood acute lymphoblastic leukemia, 1984–1999. Leukemia. 2010;24:383–396.
   Google Scholar
• Gaynon PS, Angiolillo AL, Carroll WL, et al. Long term results of the Children's Cancer Group Studies for childhood acute lymphoblastic leukemia 1983–2002: a Children's Oncology Group report. Leukemia. 2010;24:285–297.
   Google Scholar
• Salzer WL, Devidas M, Carroll WL, et al. Long-term results of the Pediatric Oncology Group studies for childhood acute lymphoblastic leukemia 1984–2001: a report from the Children's Oncology Group. Leukemia. 2010;24:355–370.
   Google Scholar
• Stark B, Nirel R, Avrahami G, et al. Long-term results of the Israeli National Studies in childhood acute lymphoblastic leukemia: INS 84, 89 and 98. Leukemia. 2010;24:419–424.
   Google Scholar
• Liang D-C, Yang C-P, Lin D-T, et al. Long-term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia. Leukemia. 2010; 24: 397–405.
   Google Scholar
• Lazic J, Tosic N, Dokmanovic N, et al. Clinical features of the most common fusion genes in childhood acute lymphoblastic leukemia. Med Oncol. 2010;27:449–453.
   Google Scholar
• Burmeister T, Gokbuget N, Schwartz S, et al. Clinical features and prognostic implications of TCF3/PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia. Haematologica. 2010;95: 241–246.
   Google Scholar
• Borowitz MJ., Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood. 2008;111:5477–5485.
   Google Scholar
• Ratei R, Basso G, Dworzak M, et al. Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction. Leukemia. 2009;23;528–534.
   Google Scholar